Formosa Laboratories Inc (4746) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Formosa Laboratories Inc stock TWD 57.59, price TWD 44.70, upside +28.8%, quality 51 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 43.75 TWD – 117.00 TWD · fair‑value band 33.57 TWD – 78.00 TWD · the 44.70 TWD price screens below the 57.59 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Formosa Laboratories in your weekly email
Every Wednesday you see whether Formosa Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally.
Show moreShow less
It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others.
The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services.
In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support.
Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.
Stock analysis
Formosa Laboratories Inc (4746) currently trades at 44.70 TWD, while our model-based Fair Value estimate is 57.59 TWD, implying the stock looks roughly 22% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 74.90 TWD per share, and 16 of the 26 models we run sit above the 44.70 TWD price.
Bear case: the Earnings-Based group reads lowest at 32.85 TWD, and 10 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 33.57 TWD (bear) to 78.00 TWD (bull), the price of 44.70 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Formosa Laboratories Inc reported revenue of 4.9B TWD in FY2025 versus 3.1B TWD in FY2021, a compound +11.5%/yr. Reported net income was 441M TWD in FY2025, compounding −22.9%/yr from FY2021.
Key figures
Market cap 5.6B TWD (≈ $170M) Micro · P/E ratio 11.4 · P/S ratio 1.20 · EPS (TTM) 3.91 TWD · Dividend yield 6.7% · Net margin 10.3% · Return on equity 4.7% · Return on assets (EBIT) 5.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 29%, 4746 screens cheaper than that median.
Fair Value models
Bear33.57 TWDFair Value 57.59 TWDBull78.00 TWD
Price 44.70 TWD · Upside +28.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.7804 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF29.70 TWD44.46 TWD63.30 TWD80
Growth DCF29.86 TWD42.68 TWD58.05 TWD79
Owner Earnings24.86 TWD37.67 TWD54.00 TWD76
All 26 models by family
DCF Models
FCF DCF29.70 TWD44.46 TWD63.30 TWD80
Owner Earnings24.86 TWD37.67 TWD54.00 TWD76
5Y Revenue Exit41.84 TWD72.11 TWD110.70 TWD71
5Y EBITDA Exit68.86 TWD122.35 TWD184.77 TWD74
5Y P/E Exit39.49 TWD67.75 TWD97.14 TWD70
10Y Revenue Exit34.64 TWD58.75 TWD90.89 TWD65
10Y EBITDA Exit51.26 TWD89.42 TWD140.47 TWD67
10Y P/E Exit34.76 TWD56.08 TWD81.82 TWD63
Earnings-Based
Graham-Dodd24.94 TWD75.82 TWD100.60 TWD65
Lynch FV16.23 TWD23.18 TWD30.14 TWD61
PEG = 1.016.23 TWD23.18 TWD30.14 TWD57
EPV36.95 TWD42.51 TWD47.08 TWD74
Dividend Discount
Gordon GGM21.99 TWD38.04 TWD50.64 TWD68
DDM Multi-Stage21.99 TWD33.23 TWD40.81 TWD67
Multiples
P/E Multiple60.52 TWD80.70 TWD100.87 TWD63
P/S Multiple46.77 TWD62.36 TWD77.95 TWD58
P/B Multiple51.81 TWD69.09 TWD86.36 TWD55
EV/EBIT64.63 TWD93.01 TWD121.40 TWD65
EV/EBITDA97.54 TWD136.90 TWD176.26 TWD67
EV/Revenue40.25 TWD66.30 TWD92.34 TWD52
Asset-Based
NCAV (Graham)30.78 TWD41.25 TWD61.57 TWD54
Growth DCF
Growth DCF29.86 TWD42.68 TWD58.05 TWD79
Rev-Margin DCF41.84 TWD72.00 TWD106.32 TWD72
Economic Profit
Residual Income47.00 TWD47.56 TWD49.80 TWD76
ROIC Compounder36.95 TWD42.51 TWD47.08 TWD72
Growth Earnings
Growth-Adj P/E49.41 TWD70.58 TWD91.76 TWD67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Start year 2020 (pandemic). Over 10 years: +6.4% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +10.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.4%
Dividend (yield on the price)6.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−9.8% vs 3.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 17%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 213% above its own trend.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +5.9% a year for the price.
Compare Formosa Laboratories Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+28.8% · Top 25%
Profitability
Return on equity (12 months)4.7% · Below median
Return on assets3.2% · Below median
Net margin (12 months)10.3% · Above median
Operating margin (12 months)7.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)−10.6% · Bottom 25%
Dividend yield (12 months)6.7% · Top 25%
Balance sheet
Debt / equity0.25× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.4× · Cheapest 25%
P/B0.72× · Cheapest 25%
P/S (12 months)1.20× · Cheaper than median
Price / free cash flow (fiscal year)11.8× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Formosa Laboratories Inc (4746) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 57.59 TWD versus a price of 44.70 TWD, about +29% upside (undervalued).
What is the fair value of 4746?
Our model-based fair value for Formosa Laboratories Inc is 57.59 TWD (as of Nov 8, 2026), built from audited fundamentals. The current price: 44.70 TWD.
What is the quality score of 4746?
Formosa Laboratories Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Formosa Laboratories Inc (4746)?
Our model-based price target is the fair value of 57.59 TWD (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 33.57 TWD, optimistic scenario 78.00 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Formosa Laboratories Inc stock forecast for 2026?
Our models put fair value at 57.59 TWD, about +29% upside versus a price of 44.70 TWD (undervalued). Cautious scenario 33.57 TWD, optimistic scenario 78.00 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Formosa Laboratories Inc (4746)?
Formosa Laboratories Inc reported trailing-twelve-month revenue of about 4.6B TWD (latest available figure, as of Nov 8, 2026).
Does Formosa Laboratories Inc pay a dividend?
Formosa Laboratories Inc currently shows a dividend yield of 6.71% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Formosa Laboratories Inc (4746) and when is the ex-dividend date?
Formosa Laboratories Inc pays a dividend of 3.00 TWD per share a year, a dividend yield of 6.7%. The last ex-dividend date was Aug 24, 2026. The payout ratio is 76.7% of earnings. Free cash flow covers the dividend 1.31 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Formosa Laboratories Inc (4746)?
For today's price to be fair in a discounted-cash-flow model, Formosa Laboratories Inc would have to grow free cash flow by +7.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.5 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 4746 use?
Our models discount Formosa Laboratories Inc at 11.8 %: a base by market capitalisation (micro), damped by beta 0.46, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Formosa Laboratories Inc that is +7.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Formosa Laboratories Inc (4746) delivered so far?
Over the past 5 years revenue at Formosa Laboratories Inc grew +9.5 % a year. The price currently implies free-cash-flow growth of +7.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Formosa Laboratories Inc (4746) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Formosa Laboratories Inc (+7.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Formosa Laboratories Inc (4746)?
The free-cash-flow yield on the price is 8.46 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Formosa Laboratories Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Formosa Laboratories Inc (4746)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Formosa Laboratories Inc it is 57.59 TWD per share (as of Nov 8, 2026), against a price of 44.70 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Formosa Laboratories Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 4746 trades below its calculated fair value: price 44.70 TWD, fair value 57.59 TWD, a gap of about +29% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4746?
No. The price is what the market pays today (44.70 TWD); the fair value is what the company's own numbers justify (57.59 TWD). For Formosa Laboratories Inc the two are 12.89 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Formosa Laboratories Inc worth?
The market values Formosa Laboratories Inc at about 5.6B TWD (market capitalisation, as of Nov 8, 2026). Per share that is 44.70 TWD; our models calculate a fair value of 57.59 TWD per share.
What do the bullish and bearish scenarios say about 4746?
Our models span a range for Formosa Laboratories Inc: cautious scenario 33.57 TWD, base 57.59 TWD, optimistic 78.00 TWD per share (as of Nov 8, 2026, price 44.70 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4746?
Formosa Laboratories Inc trades at a price-to-earnings ratio of 11.4 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 57.59 TWD is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 27.7. Other multiples: P/B 0.7, P/S 1.2, EV/EBITDA 5.2.
How solid is the balance sheet of Formosa Laboratories Inc (4746)?
Balance-sheet figures for Formosa Laboratories Inc (as of Nov 8, 2026): return on equity 4.7%, debt of 0.25 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 4746 from its 52-week high?
Formosa Laboratories Inc trades at 44.70 TWD, about 32% below its 52-week high of 65.90 TWD and 2% above the low of 43.75 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 57.59 TWD is for.
Which stocks are comparable to Formosa Laboratories Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Formosa Laboratories Inc stock attractive at the current price?
The data as of Nov 8, 2026: price 44.70 TWD, calculated fair value 57.59 TWD (+29%), Quality Score 51/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4746 calculated?
We run Formosa Laboratories Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 57.59 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Formosa Laboratories Inc currently trades 22% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Formosa Laboratories Inc (4746)?
The closing price on Nov 9, 2026 was 44.70 TWD. Our model-based fair value is 57.59 TWD, about +29% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Formosa Laboratories Inc right now?
Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (33.57 TWD to 78.00 TWD) leaves room in how you read the outcome.
Where does the earnings growth of Formosa Laboratories Inc (4746) come from?
Earnings per share at Formosa Laboratories Inc grew −6.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.4 %, EBIT margin +0.5 %, tax rate −2.9 %, residual (interest, one-offs) −7.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Formosa Laboratories Inc
How large is the market capitalisation of Formosa Laboratories Inc (4746)?
The market capitalisation of Formosa Laboratories Inc is 5.6B TWD (≈ $170M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Formosa Laboratories Inc (4746)?
The price-to-sales ratio of Formosa Laboratories Inc is 1.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Formosa Laboratories Inc (4746)?
Earnings per share at Formosa Laboratories Inc are 3.91 TWD (price ÷ EPS = P/E 11.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Formosa Laboratories Inc (4746)?
The dividend yield of Formosa Laboratories Inc is 6.7% (payout 76.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Formosa Laboratories Inc (4746)?
The net margin of Formosa Laboratories Inc is 10.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Formosa Laboratories Inc (4746)?
The return on equity (ROE) of Formosa Laboratories Inc is 4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Formosa Laboratories Inc (4746)?
On an EBIT basis the return on assets of Formosa Laboratories Inc is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Formosa Laboratories Inc (4746)?
The operating margin of Formosa Laboratories Inc is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Formosa Laboratories Inc (4746)?
Revenue at Formosa Laboratories Inc is growing −10.6% versus a year earlier (3y avg +8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Formosa Laboratories Inc (4746)?
Earnings per share at Formosa Laboratories Inc are growing −85.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Formosa Laboratories Inc (4746) carry?
The net debt of Formosa Laboratories Inc is 2.5B TWD (fiscal year 2025, ≈ 5.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Formosa Laboratories Inc in the live analysis
One click puts Formosa Laboratories Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026